Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab in Moderate-to-Severe COPD
NCT04701983Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2020
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of itepekimab in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Dec 2020; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04701983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701983.